Intelligent Bio Solutions Previews FDA Submission Strategy in Upcoming Fireside Chat
Event summary
- Intelligent Bio Solutions (Nasdaq: INBS) will host a virtual fireside chat on September 24, 2026, at 4:30 p.m. ET.
- CEO Harry Simeonidis and VP of Product Development Peter Passaris will discuss FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System.
- Topics include clinical data, FDA review process, and international commercial progress.
- Live Q&A session and replay available post-event.
The big picture
Intelligent Bio Solutions is positioning itself at the forefront of non-invasive drug screening technology, aiming to revolutionize workplace safety testing. The upcoming FDA submission for its Intelligent Fingerprinting Drug Screening System marks a critical juncture, as regulatory approval could accelerate adoption in safety-sensitive industries. The company's international commercial progress suggests growing demand, but scaling this momentum while navigating U.S. regulatory hurdles will be key.
What we're watching
- Regulatory Timing
- How the FDA review process will impact the commercialization timeline for the Intelligent Fingerprinting Drug Screening System.
- Market Expansion
- Whether Intelligent Bio Solutions can sustain its commercial progress outside the U.S. while navigating FDA approvals.
- Technology Adoption
- The pace at which safety-critical industries will adopt non-invasive drug screening solutions.